Evidence map›Paper›PMID 36368466›Full record

ArticleBone2023

The PYY/Y2R-deficient male mouse is not protected from bone loss due to Roux-en-Y gastric bypass.

Bita Zahedi, Eileen J Daley, Daniel J Brooks, Michael Bruce, R Leigh Townsend, Hans-Rudolf Berthoud, Mary L Bouxsein, Elaine W Yu

Open access · greenAbstract read
In one paragraph

Article in Bone, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bita ZahediEndocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States of America. Electronic address: bzahedi@partners.org.
Eileen J DaleyEndocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States of America.
Daniel J BrooksEndocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States of America.
Michael BruceEndocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States of America.
R Leigh TownsendNeurobiology of Nutrition & Metabolism Department, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, United States of America.
Hans-Rudolf BerthoudNeurobiology of Nutrition & Metabolism Department, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, United States of America.
Mary L BouxseinEndocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States of America.
Elaine W YuEndocrine Unit, Massachusetts General Hospital, Boston, MA 02114, United States of America.
Massachusetts General Hospital · USLouisiana State University System · US

Funding

TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Karen K Miller · 1986 to 2026
$18.5M
Translational Imaging and Phenotyping CoreP30AR075042 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI MARY L BOUXSEIN, PAOLA DIVIETI PAJEVIC · 2019 to 2026
$7.4M
Neural mechanisms controlling food intake and body weight after bariatric surgeryR01DK047348 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI BERTHOUD, HANS-RUDOLF · 1994 to 2018
$5.0M
NIAMS NIH HHS P30 AR075042NIDDK NIH HHS R01 DK047348NIDDK NIH HHS T32 DK007028
6 · The paper itself

Abstract

backgroundPeptide YY (PYY) is an anorexigenic gut hormone that also has anti-osteogenic effects, inhibiting osteoblastic activity and inducing catabolic effects. It has been postulated that increases in PYY after Roux-en-Y gastric bypass (RYGB) contribute to declines in bone mineral density (BMD) and increases in bone turnover. The aim of this study is to determine the role of the PYY Y2-receptor in mediating bone loss post-RYGB in mice.

methodsWe compared adult male wildtype (WT) and PYY Y2 receptor-deficient (KO) C57BL/6 mice that received RYGB (WT: n = 8; KO: n = 9), with sham-operated mice (Sham; WT: n = 9; KO: n = 10) and mice that were food-restricted to match the weights of the RYGB-treated group (Weight-Matched, WM; WT: n = 7; KO: n = 5). RYGB or sham surgery was performed at 15-16 weeks of age, and mice sacrificed 21 weeks later. We characterized bone microarchitecture with micro-computed tomography (μCT) at the distal femur (trabecular) and femoral midshaft (cortical). Differences in body weight, bone microarchitecture and biochemical bone markers (parathyroid hormone, PTH; C-telopeptide, CTX; and type 1 procollagen, P1NP) were compared using 2-factor ANOVA with Tukey's adjustments for multiple comparisons.

resultsBody weights were similar in the WT-RYGB, WT-WM, KO-RYGB, and KO-WM: 41-44 g; these groups weighed significantly less than the Sham surgery groups: 55-57 g. Trabecular BMD was 31-43 % lower in RYGB mice than either Sham or WM in WT and KO groups. This deficiency in trabecular bone was accompanied by a lower trabecular number (19 %-23 %), thickness (22 %-30 %) and increased trabecular spacing (25 %-34 %) in WT and KO groups (p < 0.001 for all comparisons vs. RYGB). RYGB led to lower cortical thickness, cortical tissue mineral density, and cortical bone area fraction as compared to Sham and WM in WT and KO groups (p ≤ 0.004 for all). There were no interactions between genotype and bone microarchitecture, with patterns of response to RYGB similar in both WT and KO groups. CTX and P1NP were significantly higher in RYGB mice than WM in WT and KO groups. PTH did not differ among groups.

conclusionsRYGB induced greater trabecular and cortical deficits and high bone turnover than observed in weight-matched mice, with a similar pattern in the WT and Y2RKO mice. Thus, skeletal effects of RYGB are independent of weight loss, and furthermore, PYY signaling through Y2R is not a key mediator of bone loss post-RYGB.

Indexed as

Bone Diseases, MetabolicGastric BypassAnimalsBone DensityMaleMiceMice, Inbred C57BLPeptide YYX-Ray MicrotomographyPeptide YYBariatric surgeryBone biomarkerBone lossBone microarchitectureMouse models

Identifiers

PMID36368466
PMCPMC10064867
OpenAlexW4308527726

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.